Lipotropic (MIC) injections

Methionine-inositol-choline ("MIC") injectable blends, usually with B12 and sometimes carnitine, marketed as "fat-burning" or "energy" shots in aesthetics and wellness settings.

Lipotropic injections are vitamin and amino acid blends — typically some combination of methionine, inositol, choline (the "MIC" blend) and B12, sometimes with added B vitamins or L-carnitine. The proposed mechanism is that these compounds participate in fat metabolism in the liver, so supplying them should accelerate fat loss. That is a real biochemical role and a false inference: participating in a pathway does not mean supplying more speeds it up, particularly in someone who is not deficient. This is the same reasoning error behind "B vitamins for energy".

The components are real nutrients with real roles in fat metabolism — and that mechanistic story is the entire pitch. Controlled trials showing MIC injections cause fat loss in humans do not exist. B12 injections help people who are deficient; in replete people the energy effect performs at placebo scale.

• NONE SHOWN for the injectable MIC combination — no controlled trial demonstrates it causes weight loss. Be precise about the components though: meta-analyses of oral L-carnitine across dozens of trials have found small, heterogeneous reductions in weight or fat mass. That is oral carnitine, not a compounded injection, and it does not transfer.
• B12 injections do correct B12 deficiency, which is real and worth treating — but that is a different claim from fat loss, and most people receiving these blends have not been tested for deficiency.
• Choline deficiency causes liver problems and choline is genuinely essential, which is again a different claim from accelerating fat loss in someone who is replete.
• These are typically given in weight-loss clinics alongside a calorie-restricted diet. That concurrent diet is precisely why observed weight change cannot be attributed to the injection — not proof the injection did nothing, but proof that nobody can tell.
• No FDA-approved MIC combination exists. Some patient-specific or outsourcing-facility products may qualify for statutory compounding exemptions, but that is an exemption from certain requirements — not approval, and not FDA verification of safety, effectiveness or quality. FDA has cited pharmacies over lipotropic injection products specifically.

Composition varies between clinics and is often not standardised, so two courses of "lipotropic injections" may not contain the same things. These are typically compounded injectables whose quality and clinical effectiveness have not been FDA-verified.

Modest by this catalog's standards but not zero: injection-site reactions, sterility uncertainty in products from unregulated compounders, and niacin-flush or GI effects from some blend variants. The main cost is recurring money spent on a plausible-sounding blend doing what a diet change was doing anyway.

• Anyone being sold them as a fat-loss treatment, which is the use with no supporting evidence
• Anyone who has not been tested for the deficiencies the blend claims to correct
• Anyone pregnant or breastfeeding, without clinician input on the specific composition
• Anyone on methotrexate or anti-epileptic medication, without a clinician reviewing the blend

• Interactions depend entirely on what is in the blend, which is why the composition matters more than the category name.
• If folate is present: methotrexate and some anti-epileptics interact with folate-pathway nutrients, and folate can mask undiagnosed B12 deficiency while nerve damage continues.
• If carnitine is present: labelling reports raised INR with warfarin and worsening of seizure disorders.
• If high-dose B6 is present: chronic intake is linked with sensory nerve damage.

• Whether you were actually tested for a deficiency before being sold a correction for one.
• What is actually in the syringe, since composition varies and these are typically compounded.
• Injection site reactions and any sign of infection — and, depending what is actually in the blend, more than local risk. Injectable B12 labelling carries anaphylactic shock and death, cobalt hypersensitivity, risk in early Leber optic neuropathy, and potassium disturbance during intensive treatment of severe anaemia. Injectable carnitine labelling carries serious hypersensitivity and seizures.
• The diet running alongside it, which is what any weight change is coming from.

These nutrients are not known to cause a characteristic withdrawal syndrome, though what stopping means depends on the actual formulation and on whether a diagnosed deficiency was being treated — if it was, it returns unless addressed another way. Since weight change during a course cannot be attributed to the injection, what happens afterwards is determined by whatever dietary change was running alongside it.

US: legitimate versions exist only under pharmacy-compounding rules; anything else is an unapproved injectable.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Clinical study of the lipotropic activity of the preparation Fosfolip
  Minerva Med, 1983

Not auto-graded. This entry covers several different drugs, or a use the published research was never about, so no single letter honestly describes it. The reading below is real literature — read it against what this page says, not as a score.

• XBP1-mediated activation of the STING signalling pathway in macrophages contributes to liver fibrosis progressionJHEP Rep · 2022
• InositolNutr Rev · 1978
• Metabolomics-A Promising Approach to Pituitary AdenomasFront Endocrinol (Lausanne) · 2018
• Time-restricted feeding ameliorates MCDD-induced steatohepatitis in micebioRxiv · 2023
• Further observation on the lipotropic action of choline and inositolRev Can Biol · 1948
• Lipotropic activity of choline, betaine, and methionine in ducklingsCan J Res E Med Sci · 1949
• Lead-induced ER calcium release and inhibitory effects of methionine choline in cultured rat hippocampal neuronsToxicol In Vitro · 2013
• LIPOCAICNutr Rev · 1955
• MPTP mediated Ox-mtDNA release inducing macrophage pyroptosis and exacerbating MCD-induced MASH via promoting the ITPR3/Ca(2+)/NLRP3 pathwayJ Transl Med · 2025
• Time-Restricted Feeding Ameliorates Methionine-Choline Deficient Diet-Induced Steatohepatitis in MiceInt J Mol Sci · 2024
• New hypotheses for the health-protective mechanisms of whole-grain cereals: what is beyond fibre?Nutr Res Rev · 2010
• Plant-based foods as a source of lipotropes for human nutrition: a survey of in vivo studiesCrit Rev Food Sci Nutr · 2013